Last updated: 01/03/2019 06:11:00

A study to estimate the occurrence of rotavirus gastroenteritis in children < 5 years of age, in Bulgaria and Latvia

GSK study ID
116621
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Finalized
Finalized
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: An observational study to estimate the disease burden of rotavirus gastroenteritis in infants/children less than five years of age in primary care settings, in Bulgaria and Latvia
Trial description: This study aims to estimate the real situation of rotavirus gastroenteritis (RV GE) in the primary care settings of both Bulgaria and Latvia in children less than 5 years of age.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:

Number of RV GE cases among the acute gastroenteritis (AGE) cases reported at primary care settings in infants/children less than five years of age.

Timeframe: At the time of enrollment of each subject (Day 0).

Secondary outcomes:

Symptoms related to AGE and their measures, stratified by rotavirus status for all the AGE cases reported by infants/children less than five years of age at the primary care settings.

Timeframe: Day 0 – Day 14+5 (At the time of phone call follow-up contact).

Number of RV GE cases reported at each month by infants/children less than five years of age reported at the primary care settings.

Timeframe: At the time of enrollment of each subject (Day 0).

Number of hospitalisations for RV GE and AGE, reported at the primary care settings.

Timeframe: At the time of phone call follow-up contact (14 to 19 days after enrollment).

Interventions:
Other: Stool sample
Other: Data collection
Enrollment:
1266
Observational study model:
Cohort
Primary completion date:
2014-30-06
Time perspective:
Prospective
Clinical publications:
Not applicable
Medical condition
Infections, Rotavirus
Product
SB444563
Collaborators
Not applicable
Study date(s)
December 2012 to June 2014
Type
Observational
Phase
4

Participation criteria

Sex
Female & Male
Age
Not applicable - 5 years
Accepts healthy volunteers
No
  • Infants/children with home visits by the GPGP/paediatrician for the treatment of AGE or brought to the GP/paediatrician for AGE treatment during the study period.
  • A male or female infant/child less than five years of age at the time of the GP/paediatrician visit. A child becomes ineligible on the day of her/his fifth birthday.
  • Child in care.

Trial location(s)

Location
Status
Contact us
Contact us
Location
GSK Investigational Site
Riga, Latvia, LV-1011
Status
Study Complete
Location
GSK Investigational Site
Burgas, Bulgaria, 8000
Status
Study Complete
Location
GSK Investigational Site
Ventspils, Latvia, LV-3601
Status
Study Complete
Location
GSK Investigational Site
Sofia, Bulgaria, 1528
Status
Study Complete
Location
GSK Investigational Site
Riga, Latvia, LV-1001
Status
Study Complete
Location
GSK Investigational Site
Stara Zagora, Bulgaria, 6000
Status
Study Complete
Location
GSK Investigational Site
Plovdiv, Bulgaria, 4000
Status
Study Complete
Location
GSK Investigational Site
Pleven, Bulgaria, 5800
Status
Study Complete
Location
GSK Investigational Site
Ventspils, Latvia, LV-3602
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Jelgava, Latvia, LV-3002
Status
Study Complete
Location
GSK Investigational Site
Tukums, Latvia, LV-3101
Status
Study Complete
Location
GSK Investigational Site
Veliko Turnovo, Bulgaria, 5000
Status
Study Complete
Location
GSK Investigational Site
Jelgava, Latvia, LV-3007
Status
Study Complete
Location
GSK Investigational Site
Erglu pagasts, Latvia, LV-4840
Status
Study Complete
Location
GSK Investigational Site
Kuldiga, Latvia, LV-3300
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Riga, Latvia, LV-1082
Status
Study Complete
Location
GSK Investigational Site
Ogre, Latvia, LV-5001
Status
Study Complete
Location
GSK Investigational Site
Daugavpils, Latvia, LV-5401
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Rezekne, Latvia, LV-4604
Status
Study Complete
Location
GSK Investigational Site
Bauska, Latvia, LV-3901
Status
Study Complete
Location
GSK Investigational Site
Madona, Latvia, LV-4801
Status
Study Complete
Location
GSK Investigational Site
Dobrich, Bulgaria, 9300
Status
Study Complete
Location
GSK Investigational Site
Ropazi, Latvia, LV-2135
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Liepaja, Latvia, LV-3401
Status
Study Complete
Location
GSK Investigational Site
Broceni, Latvia, LV-3851
Status
Study Complete
Location
GSK Investigational Site
Ozolnieki, Latvia, LV-3018
Status
Study Complete
Location
GSK Investigational Site
Druva, Latvia, LV-3862
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Burgas, Bulgaria, 8018
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Daugavpils, Latvia, LV-5410
Status
Study Complete
Location
GSK Investigational Site
Riga, Latvia, LV-1050
Status
Study Complete
Location
GSK Investigational Site
Varna, Bulgaria, 9000
Status
Study Complete
Location
GSK Investigational Site
Ikskile, Latvia, LV-5052
Status
Study Complete
Location
GSK Investigational Site
Pinki, Latvia, LV-2107
Status
Study Complete
Location
GSK Investigational Site
Balvi, Latvia, LV-4501
Status
Study Complete
Location
GSK Investigational Site
Riga, Latvia, LV-1024
Status
Study Complete
Location
GSK Investigational Site
Valmiera, Latvia, LV-4200
Status
Study Complete
Location
GSK Investigational Site
Riga, Latvia, LV-1010
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Sliven, Bulgaria, 8800
Status
Study Complete
Location
GSK Investigational Site
Riga, Latvia, LV-1012
Status
Study Complete
Location
GSK Investigational Site
Jelgava, Latvia, LV-3001
Status
Study Complete
Location
GSK Investigational Site
Riga, Latvia, LV-1063
Status
Study Complete
Location
GSK Investigational Site
Livani, Latvia, LV-5316
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Jekabpils, Latvia, LV-5201
Status
Study Complete
Location
GSK Investigational Site
Pazardzik, Bulgaria, 4400
Status
Study Complete
Location
GSK Investigational Site
Vangazi, Latvia, LV-2136
Status
Study Complete
Location
GSK Investigational Site
Jelgava, Latvia, LV-3008
Status
Study Complete
Location
GSK Investigational Site
Ruse, Bulgaria, 7000
Status
Study Complete
Location
GSK Investigational Site
Valmiera, Latvia, LV-4201
Status
Study Complete
Location
GSK Investigational Site
Carnikava, Latvia, LV-2163
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Riga, Latvia, LV-1002
Status
Study Complete
Location
GSK Investigational Site
Sigulda, Latvia, LV-2150
Status
Study Complete
Location
GSK Investigational Site
Limbazi, Latvia, LV-4001
Status
Study Complete
Location
GSK Investigational Site
Grobina, Latvia, LV-3430
Status
Study Complete
Location
GSK Investigational Site
Balvi, Latvia, LV-450
Status
Study Complete
Location
GSK Investigational Site
Daugavpils, Latvia, LV-540
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Druva, Latvia, LV-386
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Jekabpils, Latvia, LV-520
Status
Study Complete
Location
GSK Investigational Site
Liepaja, Latvia, LV-340
Status
Study Complete
Location
GSK Investigational Site
Madona, Latvia, LV-480
Status
Study Complete
Location
GSK Investigational Site
Ozolnieki, Latvia, LV-301
Status
Study Complete
Location
GSK Investigational Site
Pinki, Latvia, LV-210
Status
Study Complete
Location
GSK Investigational Site
Riga, Latvia, LV-101
Status
Terminated/Withdrawn
Location
GSK Investigational Site
Riga, Latvia, LV-106
Status
Study Complete
Location
GSK Investigational Site
Tukums, Latvia, LV-310
Status
Study Complete
Location
GSK Investigational Site
Ventspils, Latvia, LV-360
Status
Study Complete

Study documents

No study documents available.

Results overview

No study documents available

Recruitment status
Finalized
Actual primary completion date
2014-30-06
Actual study completion date
2014-30-06

Plain language summaries

Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.

Additional information about the trial

Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website